8/4/2011<br />TapImmune Inc<br />www.tapimmune.com<br />OTCBB: TPIV<br />OTC BB:TPIV<br />
8/4/2011<br />TapImmune Inc<br />Cautionary Statement Regarding Forward Looking Statements<br />     Certain statements co...
8/4/2011<br />TapImmune Inc<br />“ Development of Immunotherapies for cancer & infectious disease”<br />
8/4/2011<br />TapImmune Inc<br />Market for Immunotherapies/Vaccines<br />Fastest growing segment of pharmaceutical market...
8/4/2011<br />TapImmune Inc<br />TAP Technology Platform<br />TAP – Transporters associated with antigen presentation<br /...
8/4/2011<br />TapImmune Inc<br />TAP is “switched off” in Cancer<br />Many tumors have low or no expression of TAP<br />Tu...
8/4/2011<br />TapImmune Inc<br />Need to Augment TAP levels in Infectious Disease<br />Viral infections produce a range of...
8/4/2011<br />TapImmune Inc<br />Role of TAP (TAP1/TAP2) in loading peptides to MHC Class I molecules and presentation to ...
8/4/2011<br />TapImmune Inc<br />TAP treatment restores Immune Recognition in Cancer<br />TAP<br />Tumor cells now visible...
8/4/2011<br />TapImmune Inc<br />TAP Enhances Immune Recognition in<br />Infectious Disease<br />TAP<br />Greater number o...
8/4/2011<br />TapImmune Inc<br />Efficacy of TAP vector technology<br />Cancer:<br />Mouse models of metastatic melanoma a...
8/4/2011<br />TapImmune Inc<br />Clinical Development:HER2/neu +ve Breast Cancer Vaccine<br />Combination of TAP + HER2/ne...
8/4/2011<br />TapImmune Inc<br />ResearchSmallpox/Biodefense Vaccines<br />TAP improved potency of smallpox vaccine by 100...
8/4/2011<br />TapImmune Inc<br />Leverage of Collaborations<br />Crucell NV<br />TAP manufacturing<br />Research Collabora...
8/4/2011<br />TapImmune Inc<br />Advisors & R&D Team<br />Mac Cheever (Corixa; Fred Hutchinson Cancer Center)<br />Mark Re...
8/4/2011<br />TapImmune Inc<br />Corporate Profile<br />www.tapimmune.com<br /><ul><li>Technology discovery at University ...
Founded as a public corporation on OTCBB (TPIV)
Based in Seattle, WA
Upcoming SlideShare
Loading in …5
×

TapImmune Presentation

574 views

Published on

Presentation for Investors and those looking to be educated on our company.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
574
On SlideShare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

TapImmune Presentation

  1. 1. 8/4/2011<br />TapImmune Inc<br />www.tapimmune.com<br />OTCBB: TPIV<br />OTC BB:TPIV<br />
  2. 2. 8/4/2011<br />TapImmune Inc<br />Cautionary Statement Regarding Forward Looking Statements<br /> Certain statements contained herein are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company’s plan of operations and finances, the potential for the Company’s vaccines and proposed clinical trials. <br /> The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof.<br />
  3. 3. 8/4/2011<br />TapImmune Inc<br />“ Development of Immunotherapies for cancer & infectious disease”<br />
  4. 4. 8/4/2011<br />TapImmune Inc<br />Market for Immunotherapies/Vaccines<br />Fastest growing segment of pharmaceutical market:<br />Cancer:<br />Projected $6 billion U.S. for cancer vaccines by 2010 with CAGR of 70-100% <br />Stimulated by recent approvals of Dendreon’s Provenge and BMS Yervoy<br />Infectious Disease:<br />Projected market for 2010 - $11 billion<br />Viral pandemics, societal pathogens, bio-defense<br />
  5. 5. 8/4/2011<br />TapImmune Inc<br />TAP Technology Platform<br />TAP – Transporters associated with antigen presentation<br />Key component in immune recognition pathway<br />Stimulates T-cell recognition of antigens and production of cytotoxic T-cells that can infiltrate tumors<br />Patents confer broad IP protection<br />
  6. 6. 8/4/2011<br />TapImmune Inc<br />TAP is “switched off” in Cancer<br />Many tumors have low or no expression of TAP<br />Tumors not recognized as foreign by immune system<br />Diminished expression of TAP is associated with disease susceptibility, progression and metastasis <br />Vectors re-introducing TAP into tumors boost immunity and reduce tumor burden<br />
  7. 7. 8/4/2011<br />TapImmune Inc<br />Need to Augment TAP levels in Infectious Disease<br />Viral infections produce a range of viral peptides that may “overwhelm” TAP system<br />Insufficient viral antigens presented to the cellular immune system<br />Diminished expression of TAP is associated with disease susceptibility<br />Vectors augmenting normal TAP levels boost immunity and greatly improved vaccine efficacy<br />
  8. 8. 8/4/2011<br />TapImmune Inc<br />Role of TAP (TAP1/TAP2) in loading peptides to MHC Class I molecules and presentation to Cytotoxic T-cells<br />
  9. 9. 8/4/2011<br />TapImmune Inc<br />TAP treatment restores Immune Recognition in Cancer<br />TAP<br />Tumor cells now visible to the immune system<br />
  10. 10. 8/4/2011<br />TapImmune Inc<br />TAP Enhances Immune Recognition in<br />Infectious Disease<br />TAP<br />Greater number of viral antigens visible to the immune system<br />
  11. 11. 8/4/2011<br />TapImmune Inc<br />Efficacy of TAP vector technology<br />Cancer:<br />Mouse models of metastatic melanoma and small cell lung cancer:<br />Reduced metastasis<br />Higher survival <br />Infectious Disease:<br />100-1000 fold increase in efficacy of smallpox vaccine in animals.<br />
  12. 12. 8/4/2011<br />TapImmune Inc<br />Clinical Development:HER2/neu +ve Breast Cancer Vaccine<br />Combination of TAP + HER2/neu antigens from Mayo Clinic<br />applicable to ~ 80% of HER2/neu +ve patients<br />IND for Phase I studies approved<br />Current therapy: <br />Trastuzumab (Herceptin) over $5billion in annual sales<br />applicable to ~ 30% of HER2/neu +ve patients<br />
  13. 13. 8/4/2011<br />TapImmune Inc<br />ResearchSmallpox/Biodefense Vaccines<br />TAP improved potency of smallpox vaccine by 100-1000 fold<br />TAP + peptide antigens licensed from Mayo Clinic<br />Broader patient population; cheaper, longer shelf-life<br />“Animal Efficacy Rule” FDA pathway (24-36 months to potential stockpiling)<br />Potential for TAP to be stockpiled for variety of emerging bio-threats, e.g. Dengue<br />
  14. 14. 8/4/2011<br />TapImmune Inc<br />Leverage of Collaborations<br />Crucell NV<br />TAP manufacturing<br />Research Collaboration with Aeras Global TB Vaccine Foundation <br />TB antigens (Phase II clinical) + TAP<br />License Option Agreements with Mayo Clinic:<br />HER2/neu +ve breast cancer antigen technology<br /> Smallpox virus antigen technology<br />
  15. 15. 8/4/2011<br />TapImmune Inc<br />Advisors & R&D Team<br />Mac Cheever (Corixa; Fred Hutchinson Cancer Center)<br />Mark Reddish (Biomira; ID Biomedical)<br />Keith Knutson (Mayo Clinic)<br />Greg Poland (Mayo Clinic)<br />Lynn Depippo (Sherbrook Capital Management)<br />
  16. 16. 8/4/2011<br />TapImmune Inc<br />Corporate Profile<br />www.tapimmune.com<br /><ul><li>Technology discovery at University of British Columbia
  17. 17. Founded as a public corporation on OTCBB (TPIV)
  18. 18. Based in Seattle, WA
  19. 19. ~ 47 million shares outstanding (22 million in float)
  20. 20. Management & Affiliates ~ 30%</li></li></ul><li>8/4/2011<br />TapImmune Inc<br />Our Vision for TAP<br />Leading immunotherapy in the fight against cancer:<br />Multiple metastatic cancers<br />Multiple combination products<br />Early stage prophylactic use<br />Stockpiled for biodefense threats and viral pandemics:<br />Variety of infectious diseases<br />Emerging bio-terrorist threats<br />Making other vaccines more effective<br />
  21. 21. 8/4/2011<br />TapImmune Inc<br />Looking for Investors that Share our VisionWhy Invest in TPIV now?<br />Breakthrough technology<br />Strong product pipeline<br />World-class team and collaborators<br />Risk diversification – cancer & infectious disease<br />Compelling preclinical data<br />Start of clinical programs<br />Undervalued and poised for significant growth<br />

×